➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Mallinckrodt
Express Scripts
Merck
Moodys

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Litigation Details for AbbVie Inc. v. Hospira Inc. (D. Del. 2011)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in AbbVie Inc. v. Hospira Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .
Biologic Drugs cited in AbbVie Inc. v. Hospira Inc.
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for AbbVie Inc. v. Hospira Inc. (D. Del. 2011)

Date Filed Document No. Description Snippet Link To Document
2012-12-17 112 STIPULATION of Dismissal for U.S. Patent No. 6,361,758 by Abbott Laboratories, Hospira Inc., Wisconsin…2011 24 October 2014 1:11-cv-00648 830 Patent None District Court, D. Delaware External link to document
2013-01-04 115 Summary Judgment of Non-Infringement of U.S. Patent No. 6,136,799. (Attachments: # 1 Exhibit A, # 2 Exhibit…2011 24 October 2014 1:11-cv-00648 830 Patent None District Court, D. Delaware External link to document
2013-01-11 118 Summary Judgment of Non-Infringement of U.S. Patent No. 6,136,799. by Hospira Inc.. (Attachments: # 1 Exhibit…2011 24 October 2014 1:11-cv-00648 830 Patent None District Court, D. Delaware External link to document
2013-05-17 168 ORDER Construing the Terms of U.S. Patent Nos. 6,136,799 & 5,597,815. Signed by Chief Judge Gregory…2011 24 October 2014 1:11-cv-00648 830 Patent None District Court, D. Delaware External link to document
2013-05-29 170 Pinal, Ph.D. on the Invalidity of U.S. Patent Nos. 6,136,799 and 5,587,497, and (3) Expert Report of … of Jay B. Wish, M.D. on the Invalidity of U.S. Patent No. 5,597,815, (2) Opening Expert Report of Rodolfo…2011 24 October 2014 1:11-cv-00648 830 Patent None District Court, D. Delaware External link to document
2013-07-02 172 U.S. Patent No. 6,136,799; 2) Rebuttal Expert Report of Louis A. Morris, Ph.D., on U.S. Patent No. 5,…of Jay B. Wish, M.D. on Non-Infringement of U.S. Patent No. 5,597,815 by Hospira Inc..(Squire, Monte) (…2011 24 October 2014 1:11-cv-00648 830 Patent None District Court, D. Delaware External link to document
2013-12-19 190 ʼ799 patent U.S. Patent No. 6,136,799 [JTX2] ʼ925 patent U.S. Patent No. 5,246,925…Obviousness Combination—the ’957 Patent in View of the ’925 Patent Prosecution History or Malluche—Lacks…5,246,925 [JTX34] ʼ957 patent U.S. Patent No. 5,472,957 [DTX355] AbbVie Plaintiff…Hospira studied the ’799 patent and then, when its efforts to design around the patent failed, copied a preferred…Embodiment from the ʼ799 Patent 40. Hospira reviewed the ’799 patent prior to beginning work External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
McKesson
Colorcon
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.